HARNESSING ARTIFICIAL INTELLIGENCE
IN DRUG DISCOVERY
HARNESSING ARTIFICIAL INTELLIGENCE
IN DRUG DISCOVERY

Decoding the Gut-Brain Axis to Deliver Transformative Therapies

Decoding the
Gut-Brain
Axis to Deliver
Transformative
Therapies

HARNESSING ARTIFICIAL INTELLIGENCE
IN DRUG DISCOVERY

Decoding the Gut-Brain Axis to Deliver Transformative Therapies

About

DECODING THE GUT BRAIN AXIS WITH THE POWER OF ARTIFICIAL INTELLIGENCE

Invea Therapeutics, Inc. is a clinical-stage biotechnology company expediting the discovery of transformational therapeutics for inflammatory gastrointestinal and hepatobiliary disorders. The Company is harnessing the power of artificial intelligence to decode innate immunity, inflammasome biology, and neuroinflammation via the gut-brain axis to increase the probability of clinical success

About (1)

THE SCIENCE

“IT’S A GUT FEELING!”

The gut instinct! This is not an abstraction. The brain is in constant communication with the gut, also known as the second brain, linking physiology to psychology, which is why it is common to hear, “I feel it in my gut!”. The communication path between the gut and brain – The Gut-Brain Axis (GBA) – is key to maintaining good health. The GBA is influenced by the health of the gut and the brain and the bidirectional communication via the Central Nervous System (CNS), vagus nerve, and the Enteric Nervous System (ENS). A disturbance of this status is often referred to as gut dysbiosis. The immune cells in the gut are essential links in the relay of messages from the brain to the gut (afferent signals) or from the gut to the brain (efferent signals) and mediate the immune response to gut dysbiosis or other sources of Inflammation within the gut. In chronic inflammatory diseases, there is a “runaway immune response” leading to conditions such as Inflammatory Bowel Disease and Irritable Bowel Syndrome. An immunological over-reaction can lead to harmful inflammation, and signals transmitted through the GBA perpetuate these diseases and associated symptoms.

Invea Therapeutics is decoding the GBA and identifying key immune and signaling molecular players whose activity may be modulated to restore homeostasis in the gut and improve non-GI symptoms.

TECHNOLOGY PLATFORM

LEVERAGING ARTIFICIAL INTELLIGENCE TO ACCELERATE AND ENHANCE DRUG DISCOVERY INNOVATION

Invea Therapeutics is dedicated to identifying, researching, and developing treatment options that will create a lasting impact for patients around the world. In particular, we focus on gastrointestinal disorders, which continue to have a high unmet need and a costly impact on public health. We deploy an AI-powered technology platform GBAnk, developed by InveniAI®.
Executive Management
Krishnan Nandabalan, Ph.D.
Chairman, President & CEO
Salvatore Alesci, M.D., Ph.D.
Chief Scientific Officer
Steve Okada, M.D.
Chief Medical Officer
Aman Kant
Chief Business Officer
Michael Aiello, CPA
Chief Financial Officer
Patricia Spera, Ph.D.
VP, Clinical Operations
Sameer Sharma, Ph.D.
VP, Translational Drug Discovery, InveniAI
Anita Ganjoo, Ph.D.
VP, External Communications
Board of Directors
Krishnan Nandabalan, Ph.D.
Chairman, President & CEO
Invea Therapeutics
Vimal Mehta, Ph.D.
CEO & Founder
BioXcel Therapeutics
Jonathan Zalevsky, Ph.D.
Chief Research & Development Officer
Nektar Therapeutics
Demetrios Kydonieus, MBA
President
R-Pharm
Kerrie Brady, MBA, MS
CEO
OcuTerra
Steve Laumas, M.D.
CFO and CBO
Instil Bio, Inc

Invea Therapeutics

THE GUT INSTINCT

Have A Query ?

contact us

Business Inquiries :
Email: info@inveatx.com
Employment:
careers@inveatx.com
© 2021 Invea Therapeutics, Inc. All rights reserved
Privacy Policy